Lilly Alzheimer?s Drug Helped Patients in Small Trial
Companies, agencies, institutions, etc
MembershipCustomer ServiceTools & FeaturesAdsMoreDow Jones Products
People
No matching tags
Groups
No matching tags
Physical locations
No matching tags
Places
No matching tags
Locations
No matching tags
Events
No matching tags
Summary
Donanemab slowed cognitive and functional decline of patients with mild Alzheimer?s by 32% compared with placebo
As said here by Jonathan D. Rockoff